Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients

Hamzah Abu-Sbeih, Faisal S. Ali, Yinghong Wang

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Abstract: Fecal microbiota transplantation (FMT) represents a promising management modality for Clostridium difficile infection (CDI). In immunocompromised patients, FMT is utilized for CDI as well as emerging non-CDI indications such as inflammatory bowel disease and graft versus host disease. Purpose of Review: This review aims to shed light on the safety and efficacy of FMT in immunocompromised patients, including patients suffering for human immunodeficiency virus infection, solid organ and hematopoietic stem cell transplant recipients, cancer patients, and patients on immunosuppressive therapies. Recent Findings: Though the body of evidence concerning the use of FMT in immunocompromised is growing, no clinical trials exist to date. Summary: Present literature weighs in favor of FMT in immunocompromised patients, with an acceptable adverse effect profile and minimal risk of infectious adverse events. Further large scale studies and randomized controlled trials to validate the utility of FMT in immunocompromised individuals will be a welcomed endeavor.

Original languageEnglish (US)
Article number8
JournalCurrent gastroenterology reports
Volume21
Issue number4
DOIs
StatePublished - Apr 1 2019

Keywords

  • Adverse events
  • Aspiration
  • Fecal microbiota transplantation
  • Hematopoietic stem cell transplant
  • Immunosuppression
  • Infection
  • Solid organ transplant

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients'. Together they form a unique fingerprint.

Cite this